⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 28, 2024Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

Genetic signatures of ERCC1 and ERCC2 expression, along with SNPs variants, unveil favorable prognosis in SCLC patients undergoing platinum-based chemotherapy

Enrico Caliman S. Fancelli F. Scolari Adriano Pasqui Clara Manneschi Daniele Lavacchi Francesca Mazzoni Francesca Gensini Valeria Pasini Camilla Comin Luca Voltolini Serena Pillozzi Lorenzo Antonuzzo

View Full Paper

Ask AI

Bookmark

Share

Abstract

Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients' survival.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Caliman et al. (2024) studied this question.

synapsesocial.com/papers/68e62c2eb6db6435875bee33 https://doi.org/10.32604/or.2024.050161

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer2024 · 6 citations
2Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from ERCC2 rs131812024
3Lung cancer, predictive factor and ERCC12024
4Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer2025 · 11 citations
5ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer2024 · 10 citations